Dudediligence.

Intellia Therapeutics, Inc

NTLANASDAQ · In Vitro & in Vivo Diagnostic Substances
Write an idea

Insiders

Last 12 months

Sales planned on beside the trades reported on , and whether each names a .

Planned ·

$1,932,987

4 notices · 173,248 sh

Oct 2025 to Oct 2026

Reported ·

$2,140,145

17 sales · 1 buy · $1,402,500 bought

Oct 2025 to Sep 2026

The two figures cover different periods.

6 of 17 reported sales carry the 10b5-1 box. Together they are 0.15% of the shares on issue.

PLANNED · FORM 144Oct 2025 to Oct 2026REPORTED · FORM 4Oct 2025 to Sep 2026N2025DJ2026FMAMJJASO2026-10-05: ELIANA CLARK, Form 1442026-08-20: LEONARD JOHN M, Form 1442026-07-02: EDWARD DULAC, Form 1442025-12-11: LEONARD JOHN M, Form 1442025-12-11: LEONARD JOHN M, sold2026-01-05: Dube Michael P, sold2026-01-05: Dulac Edward J III, sold2026-01-05: Clark Eliana, sold2026-01-05: Lebwohl David, sold2026-01-05: Cohen Fred E, bought2026-01-05: BASTA JAMES, sold2026-01-05: Schultes Birgit C, sold2026-01-05: LEONARD JOHN M, sold2026-03-02: Clark Eliana, sold2026-03-02: BASTA JAMES, sold2026-07-01: Dube Michael P, sold2026-07-02: Dulac Edward J III, sold2026-07-22: Dulac Edward J III, sold2026-08-20: LEONARD JOHN M, sold
under a no plan named▼ sale▲ buysize is dollars

Form 144 notices, newest first

2026-10-05ELIANA CLARK, EVP, Chief Technical Officer$736,313
57,750 shno plan dateForm 4s on file end Sep 23144 ↗
2026-08-20LEONARD JOHN M, President and CEO$293,641
22,675 shplan 2026-05-21144 ↗
Form 4, 2026-08-24: sold 22,675 at $12.65 Form 4 ↗
2026-07-02EDWARD DULAC, EVP, Chief Financial Officer$80,631
4,677 shplan 2025-09-08144 ↗
Form 4, 2026-07-06: sold 4,677 at $18.00 Form 4 ↗
2025-12-11LEONARD JOHN M, President and CEO$822,402
88,146 shplan 2025-09-11144 ↗
Form 4, 2025-12-12: sold 88,146 at $9.49 Form 4 ↗